TOM: a web-based integrated approach for identification of candidate disease genes.

Nucleic Acids Res

Functional Genomics Laboratory and Telethon Facility, DAMA Data Mining for Analysis of DNA Microarrays, Dipartimento di Morfologia ed Embriologia, Via Fossato di Mortara 64b, 44100 Ferrara, Italy.

Published: July 2006

The massive production of biological data by means of highly parallel devices like microarrays for gene expression has paved the way to new possible approaches in molecular genetics. Among them the possibility of inferring biological answers by querying large amounts of expression data. Based on this principle, we present here TOM, a web-based resource for the efficient extraction of candidate genes for hereditary diseases. The service requires the previous knowledge of at least another gene responsible for the disease and the linkage area, or else of two disease associated genetic intervals. The algorithm uses the information stored in public resources, including mapping, expression and functional databases. Given the queries, TOM will select and list one or more candidate genes. This approach allows the geneticist to bypass the costly and time consuming tracing of genetic markers through entire families and might improve the chance of identifying disease genes, particularly for rare diseases. We present here the tool and the results obtained on known benchmark and on hereditary predisposition to familial thyroid cancer. Our algorithm is available at http://www-micrel.deis.unibo.it/~tom/.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1538851PMC
http://dx.doi.org/10.1093/nar/gkl340DOI Listing

Publication Analysis

Top Keywords

tom web-based
8
disease genes
8
candidate genes
8
web-based integrated
4
integrated approach
4
approach identification
4
identification candidate
4
disease
4
candidate disease
4
genes
4

Similar Publications

A hybrid machine learning approach for the personalized prognostication of aggressive skin cancers.

NPJ Digit Med

January 2025

Mike Toth Head and Neck Cancer Research Center, Division of Surgical Oncology, Department of Otolaryngology-Head and Neck Surgery, Mass Eye and Ear, Boston, MA, USA.

Accurate prognostication guides optimal clinical management in skin cancer. Merkel cell carcinoma (MCC) is the most aggressive form of skin cancer that often presents in advanced stages and is associated with poor survival rates. There are no personalized prognostic tools in use in MCC.

View Article and Find Full Text PDF
Article Synopsis
  • The COVID-19 pandemic has negatively impacted the Canadian healthcare system, particularly increasing concerns about physician burnout among medical oncologists (MOs).
  • The Canadian Association of Medical Oncologists conducted four surveys between May 2020 and March 2022 to assess the effects of the pandemic on the MO workforce, finding high levels of dissatisfaction with work-life balance and increased workloads.
  • The surveys revealed that a significant portion of MOs, particularly those with over 10 years of experience, are contemplating retirement or reducing work hours, highlighting the need to address wellness and job satisfaction to maintain a stable workforce.
View Article and Find Full Text PDF

Using Digital Instructions to Address on-Market Product Complaints and Improve User Experiences.

PDA J Pharm Sci Technol

August 2024

Team Consulting, Cambridge, United Kingdom

Manufacturers of medical devices are legally required to carry out post-market surveillance and respond to any on-market complaints they receive about their device. When it comes to addressing use issues experienced on market, manufacturers often focus on revising the instructions for use (IFU) and labeling. One of the challenges with this approach is the potential need to re-validate via a human factors validation study, without knowing whether the changes made will be effective in addressing the identified issues.

View Article and Find Full Text PDF

Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trial.

Lancet Infect Dis

October 2024

London School of Hygiene & Tropical Medicine, London, UK; Infectious Diseases Translational Research Programme and Yong Loo Lin School of Medicine, National University of Singapore, Singapore. Electronic address:

Background: Long-acting injectable cabotegravir and rilpivirine is licensed for individualised treatment of HIV-1 infection in resource-rich settings. Additional evidence is required to support use in African treatment programmes where demographic factors, viral subtypes, previous treatment, and delivery and monitoring approaches differ. The aim of this study was to determine whether switching to long-acting therapy with injections every 8 weeks is non-inferior to daily oral therapy in Africa.

View Article and Find Full Text PDF

Background: Heart failure (HF) affects 6.2 million Americans and is a leading cause of hospitalization. The mainstay of the management of HF is adherence to pharmacotherapy.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!